GLAND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,717 INR | +0.37% |
|
-0.32% | -10.79% |
| 05-07 | Gland Pharma Gets US FDA's Approval for Generic ALS Drug | MT |
| 05-07 | Gland Pharma Gets US FDA's Approval for Generic Stem Cell Mobilizer Injection | MT |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 405,432 | 537,705 | 208,882 | 281,746 | - | - |
| Enterprise Value (EV) 1 | 375,414 | 506,809 | 171,208 | 254,250 | 250,196 | 244,897 |
| P/E ratio | 39.3 x | 44.4 x | 26.7 x | 33.1 x | 25.5 x | 23 x |
| Yield | - | - | - | 0.14% | 0.25% | 0.2% |
| Capitalization / Revenue | 11.7 x | 12.2 x | 5.76 x | 4.99 x | 4.46 x | 3.98 x |
| EV / Revenue | 10.8 x | 11.5 x | 4.72 x | 4.5 x | 3.96 x | 3.46 x |
| EV / EBITDA | 28.8 x | 33.6 x | 16.7 x | 18.8 x | 15.4 x | 13.4 x |
| EV / FCF | 99.8 x | 181 x | 120 x | -22.5 x | 44.1 x | 27.5 x |
| FCF Yield | 1% | 0.55% | 0.84% | -4.45% | 2.27% | 3.64% |
| Price to Book | 6.51 x | 7.48 x | 2.62 x | 3.2 x | 2.83 x | 2.56 x |
| Nbr of stocks (in thousands) | 163,593 | 164,303 | 164,701 | 164,711 | - | - |
| Reference price 2 | 2,478 | 3,273 | 1,268 | 1,711 | 1,711 | 1,711 |
| Announcement Date | 17/05/21 | 19/05/22 | 18/05/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 26,332 | 34,629 | 44,007 | 36,246 | 56,490 | 63,200 | 70,724 |
| EBITDA 1 | - | 13,022 | 15,102 | 10,248 | 13,492 | 16,200 | 18,263 |
| EBIT 1 | - | 12,034 | 13,999 | 8,780 | 10,198 | 12,863 | 14,406 |
| Operating Margin | - | 34.75% | 31.81% | 24.22% | 18.05% | 20.35% | 20.37% |
| Earnings before Tax (EBT) 1 | - | 13,348 | 16,186 | 10,546 | 11,692 | 14,527 | 16,171 |
| Net income 1 | - | 9,970 | 12,117 | 7,810 | 8,480 | 11,024 | 12,226 |
| Net margin | - | 28.79% | 27.53% | 21.55% | 15.01% | 17.44% | 17.29% |
| EPS 2 | - | 62.99 | 73.64 | 47.43 | 51.66 | 66.98 | 74.32 |
| Free Cash Flow 1 | - | 3,762 | 2,800 | 1,430 | -11,309 | 5,667 | 8,914 |
| FCF margin | - | 10.86% | 6.36% | 3.95% | -20.02% | 8.97% | 12.6% |
| FCF Conversion (EBITDA) | - | 28.89% | 18.54% | 13.96% | - | 34.98% | 48.81% |
| FCF Conversion (Net income) | - | 37.73% | 23.11% | 18.31% | - | 51.41% | 72.91% |
| Dividend per Share 2 | - | - | - | - | 2.333 | 4.250 | 3.500 |
| Announcement Date | 10/07/20 | 17/05/21 | 19/05/22 | 18/05/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,877 | 11,539 | 10,805 | 10,633 | 11,030 | 8,569 | 10,444 | 9,383 | 7,850 | 12,087 | 13,439 | 14,508 | 15,710 | 15,977 |
| EBITDA 1 | 3,277 | 4,363 | 3,766 | 3,489 | 3,484 | 2,699 | 2,969 | 2,896 | 1,684 | 2,982 | 3,128 | 3,600 | 3,708 | - |
| EBIT 1 | 3,028 | 4,110 | 3,505 | 3,211 | 3,173 | 2,350 | 2,602 | 2,520 | 1,309 | 2,286 | 2,299 | 2,769 | 2,734 | 3,116 |
| Operating Margin | 34.1% | 35.62% | 32.44% | 30.2% | 28.77% | 27.43% | 24.91% | 26.85% | 16.67% | 18.92% | 17.11% | 19.09% | 17.4% | 19.5% |
| Earnings before Tax (EBT) 1 | 3,489 | 4,718 | 4,007 | 3,656 | 3,805 | 3,085 | 3,241 | 3,108 | 1,112 | 2,613 | 2,828 | 3,354 | 3,302 | - |
| Net income 1 | 2,604 | 3,507 | 3,021 | 2,730 | 2,859 | 2,292 | 2,412 | 2,319 | 786.8 | 1,941 | 2,161 | 2,332 | 2,336 | - |
| Net margin | 29.33% | 30.39% | 27.96% | 25.68% | 25.92% | 26.74% | 23.1% | 24.72% | 10.02% | 16.06% | 16.08% | 16.07% | 14.87% | - |
| EPS 2 | - | 21.37 | 18.37 | 16.62 | 17.36 | 13.92 | 14.65 | 14.08 | 4.780 | 11.78 | 12.70 | 13.60 | 14.23 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/05/21 | 21/07/21 | 22/10/21 | 21/01/22 | 19/05/22 | 20/07/22 | 26/10/22 | 23/01/23 | 18/05/23 | 07/08/23 | - | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 30,018 | 30,896 | 37,674 | 27,496 | 31,550 | 36,849 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 3,762 | 2,800 | 1,430 | -11,309 | 5,667 | 8,914 |
| ROE (net income / shareholders' equity) | - | 20.9% | 18.6% | 10.3% | 9.93% | 11.3% | 11.6% |
| ROA (Net income/ Total Assets) | - | 18.8% | 16.9% | 9.4% | 8.8% | 10.9% | 11.4% |
| Assets 1 | - | 52,911 | 71,651 | 83,056 | 96,366 | 101,224 | 107,246 |
| Book Value Per Share 2 | - | 381.0 | 438.0 | 483.0 | 535.0 | 605.0 | 669.0 |
| Cash Flow per Share 2 | - | - | - | 22.10 | 38.40 | 61.80 | - |
| Capex 1 | - | 2,288 | 5,113 | 2,209 | 10,447 | 4,248 | 3,289 |
| Capex / Sales | - | 6.61% | 11.62% | 6.1% | 18.49% | 6.72% | 4.65% |
| Announcement Date | 10/07/20 | 17/05/21 | 19/05/22 | 18/05/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,711
INR
Average target price
1,845
INR
Spread / Average Target
+7.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.79% | 3.38B | |
| +33.43% | 700B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +15.57% | 236B | |
| +6.56% | 202B | |
| -9.33% | 197B | |
| +4.26% | 161B | |
| -3.54% | 157B |
- Stock Market
- Equities
- GLAND Stock
- Financials Gland Pharma Limited
